


Nurofen Limited

Directors' Report and Unaudited Financial Statements

For the year ended 31 December 2018

Registered number: 00905237



Contents

	Page
Directors' Report	2
Balance Sheet	3
Statement of Changes in Equity	4
Notes to the Financial Statements	5

Nurofen Limited
Directors' Report for the year ended 31 December 2018

The Directors of Nurofen Limited ("the Company") present their report together with the unaudited Financial Statements for the year ended 31 December 2018.

Results

The Company did not trade during the current or preceding year and accordingly no Statement of Comprehensive Income has been prepared. The Company has not received any income or incurred any expense or recognised any other recognised gains or losses during the current or preceding year.

Directors

The Directors of the Company who held office during the year and up to the date of signing of the Financial Statements, unless otherwise stated, were as follows:


Jonathan Timmis
Richard Mark Greensmith

Dividends

The Directors paid £nil dividends during the year (2017: £nil).

In preparing this report, the Directors have taken advantage of the small companies' exemptions provided by section 415A of the Companies Act 2006.

Approved by the Board and signed on its behalf by:



Richard Mark Greensmith
Director

Date: 18/09/19

Balance Sheet
at 31 December 2018

	<i>Note</i>	31 December 2018 £	31 December 2017 £
Current Assets			
Debtors due within one year	2	399,865	399,865
Net Assets		<u>399,865</u>	<u>399,865</u>
 Capital and Reserves			
Share Capital	3	100	100
Retained earnings		399,765	399,765
Total Equity		<u>399,865</u>	<u>399,865</u>


For the year ended 31 December 2018 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006 (the "Act") relating to dormant companies.

The members have not required the Company to obtain an audit of its Financial Statements for the year in question in accordance with section 476 of the Act.

The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of Financial Statements.

These Financial Statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

These Financial Statements were approved by the Board of Directors and authorised for issue on 18/09/19


Richard Mark Greensmith
 Director

**Statement of Changes in Equity
 at 31 December 2018**

	Share capital £	Retained earnings £	Total £
At 31 December 2016	100	399,765	399,865
Profit for the year	-	-	-
At 31 December 2017	100	399,765	399,865
Profit for the year	-	-	-
At 31 December 2018	100	399,765	399,865

Notes to the Financial Statements

1 Accounting policies

The Financial Statements have been prepared on a going concern basis, under the historical cost convention and in compliance with United Kingdom Accounting Standards, including Financial Reporting Standard 102, "The Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland" ("FRS 102") and the Companies Act 2006.

The Company is a wholly owned subsidiary of Reckitt Benckiser Group plc (the "Group"), a company incorporated in England and Wales, which has prepared publicly available consolidated accounts which include the Company.

a) General Information

Nurofen Limited is a company incorporated in England and Wales under the Companies Act 1948, and is subject to the requirements of the Companies Act 2006. The address of the registered office is 103-105 Bath Road, Slough, Berkshire, SL1 3UH. The Company did not trade during the year.

b) Financial Reporting Standard 102 – Reduced Disclosure Exemptions

The Company has taken advantage of the following disclosure exemptions in preparing these Financial Statements, as permitted by FRS 102 for qualifying entities:

- The requirements of section 3 Financial Statement Presentation paragraph 3.17(d) and section 7 Statement of Cash Flows not to prepare a statement of cash flows;
- The requirements of section 4 Statement of Financial Position paragraph 4.12(a)(iv) not to prepare a reconciliation of the numbers of shares outstanding at the beginning and end of the year; and
- The requirements of section 33 Related Party Disclosures paragraph 33.7 not to disclose key management personnel compensation in total.

2 Debtors due within one year

	2018 £	2017 £
Amounts owed by Group undertakings	<u>399,865</u>	<u>399,865</u>

The amounts owed by Group undertakings are unsecured, repayable on demand and non-interest bearing.

3 Share capital

	2018 £	2017 £
Allotted, and fully paid		
100 Ordinary shares of £1 each	<u>100</u>	<u>100</u>

4 Ultimate controlling party

The Company is a subsidiary undertaking of RB Holdings (Nottingham) Limited, a company registered in England and Wales. Reckitt Benckiser Group plc, a company incorporated in England and Wales, is the ultimate parent company and the Directors regard it as the ultimate controlling party.

Reckitt Benckiser Group plc is the parent company of the largest and smallest group of which the Company is a member and for which group accounts are drawn up. Copies of the accounts are available from Reckitt Benckiser Group plc, 103-105 Bath Road, Slough, Berkshire, SL1 3UH or at <http://www.rb.com>.